[ 1 ] Yamashita H, Eri T, Ueda Y, et al. Diagnosis and treatment of primary Sj？gren syndrome-associated peripheral neuropathy: a six-case series[J/OL]. Mod Rheumatol, 2012. http://link.springer.com/content/pdf/10.1007%2Fs10165-012-0767-x.pdf.
[2]
[ 2 ] Brito-Zerón P, Akasbi M, Bosch X, et al. Classification and characterisation of peripheral neuropathies in 102 patients with primary Sj？gren’ s syndrome[J]. Clin Exp Rheumatol, 2012, 31(1): 103-110.
[ 6 ] Tzioufas AG, Wassmuth R, Dafni UG, et al. Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sj？gren’s syndrome (pSS): a European multicentre study[J]. Ann Rheum Dis, 2002, 61(5): 398-404.
[7]
[ 7 ] Go？b V, Salle V, Duhaut P, et al. Clinical significance of autoantibodies recognizing Sj？gren’s syndrome A(SSA), SSB, calpastatin and alpha-fodrin in primary Sj？gren’s syndrome[J]. Clin Exp Immunol, 2007, 148(2): 281-287.
Lorber M, Gershwin ME, Shoenfeld Y. The coexistence of systemic lupus erythematosus with other autoimmune diseases: the kaleidoscope of autoimmunity[J]. Semin Arthritis Rheum, 1994, 24(2): 105-113.
[10]
[ 9 ] Smole？ska Z, Pawowska J, Zdrojewski Z, et al. Increased percentage of CD8+CD28- T cells correlates with clinical activity in primary Sj？gren’s syndrome[J]. Cell Immunol, 2012, 278(1-2): 143-151.
Gono T, Kawaguchi Y, Katsumata Y, et al. Clinical manifestations of neurological involvement in primary Sj？gren’s syndrome[J]. Clin Rheumatol, 2011, 30(4): 485-490.
[14]
Pavlakis PP, Alexopoulos H, Kosmidis ML, et al. Peripheral neuropathies in Sj？gren syndrome: a new reappraisal[J]. J Neurol Neurosurg Psychiat, 2011, 82(7): 798-802.
[15]
Chai J, Herrmann DN, Stanton M, et al. Painful small-fiber neuropathy in Sjogren syndrome[J]. Neurology, 2005, 65(6): 925-927.
[16]
Dali-Youcef N, Andrès E. An update on cobalamin deficiency in adults[J]. QJM, 2009, 102(1): 17-28.
